DualityBio and Genentech Sign $45 Million Upfront, $1 Billion+ Milestone ADC Deal on DUPAC Novel-Payload Platform Targeting TOPO1 Resistance
DualityBio (HKEX: 9606) announced Friday August 28, 2026 a global collaboration and license agreement with Genentech (Roche Group) to develop next-generation antibody-drug conjugates on DualityBio's proprietary DUPAC (DualityBio Unique Payload Antibody Conjugate) platform. Terms: $45 million upfront to DualityBio plus more than $1 billion in aggregate development, regulatory, and commercial milestone payments across all programs, with tiered royalties on annual net sales. DualityBio handles discovery through Phase Ia; Genentech takes over global clinical development and commercialization. The DUPAC platform is one of DualityBio's four proprietary ADC platforms and is dedicated to payloads with novel mechanisms of action designed to address resistance to existing topoisomerase inhibitor-based ADCs (Trodelvy, Enhertu, Datroway, and successors). The deal is Genentech's second Asia-based ADC alliance in a week and continues the pattern of large pharma buying diverse payload chemistries as ADC-first-line combinations expand.